The chosen few: Mycobacterium tuberculosis isolates for IMPAc-TB.

Autor:	Larsen SE; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Abdelaal HFM; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Plumlee CR; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Cohen SB; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Kim HD; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Barrett HW; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States.; Department of Global Health, University of Washington, Seattle, WA, United States., Liu Q; Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States., Harband MH; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Berube BJ; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Baldwin SL; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States., Fortune SM; Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA, United States.; Broad Institute of Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA, United States., Urdahl KB; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States.; Department of Immunology, University of Washington, Seattle, WA, United States.; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States., Coler RN; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States.; Department of Global Health, University of Washington, Seattle, WA, United States.; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Oct 28; Vol. 15, pp. 1427510. Date of Electronic Publication: 2024 Oct 28 (Print Publication: 2024).
DOI:	10.3389/fimmu.2024.1427510
Abstrakt:	The three programs that make up the Immune Mechanisms of Protection Against Mycobacterium tuberculosis Centers (IMPAc-TB) had to prioritize and select strains to be leveraged for this work. The CASCADE team based at Seattle Children's Research Institute are leveraging M.tb H37Rv, M.tb CDC1551, and M.tb SA161. The HI-IMPACT team based at Harvard T.H. Chan School of Public Health, Boston, have selected M.tb Erdman as well as a novel clinical isolate recently characterized during a longitudinal study in Peru. The PHOENIX team also based at Seattle Children's Research Institute have selected M.tb HN878 and M.tb Erdman as their isolates of choice. Here, we describe original source isolation, genomic references, key virulence characteristics, and relevant tools that make these isolates attractive for use. The global context for M.tb lineage 2 and 4 selection is reviewed including what is known about their relative abundance and acquisition of drug resistance. Host-pathogen interactions seem driven by genomic differences on each side, and these play an important role in pathogenesis and immunity. The few M.tb strains chosen for this work do not reflect the vast genomic diversity within this species. They do, however, provide specific virulence, pathology, and growth kinetics of interest to the consortium. The strains selected should not be considered as "representative" of the growing available array of M.tb isolates, but rather tools that are being used to address key outstanding questions in the field. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Larsen, Abdelaal, Plumlee, Cohen, Kim, Barrett, Liu, Harband, Berube, Baldwin, Fortune, Urdahl and Coler.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu